Atreja 2018.
Study characteristics | ||
Methods | Randomised trial, USA. | |
Participants | 320 patients with irritable bowel syndrome. 47% female. | |
Interventions | Intervention patients update their information and receive a disease summary of quality of care metrics and IBD‐specific quality of life trends. Atreja 2018 Intervention features Multiple complex feedback (multiple PROMs at multiple times) PROM(s) used as intervention: HealthPROMISE app measuring quality of care and quality of life Constructs measured: Health related Quality of Life, Symptoms, Functioning Instrument categories/domains: Generic, Domain/Disease specific (IBD) Administration features Where PROMs administered: Non‐clinical setting How administered: Self‐administered Format of PROMs questionnaire(s): Electronic Feedback features Format of PROMs feedback: Electronic How often information fed back: Whenever HealthPROMISE patients updated their information Who information fed back to: Clinicians Information fed back: Scores |
|
Outcomes | Primary outcome was change in quality of care. Secondary outcomes were disparities in IBD‐related emergency room visits and hospitalisations, change in quality of life score from baseline, and proportion of patients reporting controlled disease status. | |
Notes | Funding information not provided. The study period is not reported. Conflicts of interest are not reported. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Abstract only. |
Allocation concealment (selection bias) | Unclear risk | Abstract only. |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Abstract only. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Abstract only. |
Baseline outcome measurements similar | Unclear risk | Abstract only. |
Baseline characteristics similar | Unclear risk | Abstract only. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Abstract only. |
Was study protected against contamination | Unclear risk | Abstract only. |
Selective reporting (reporting bias) | Unclear risk | Abstract only. |